176 related articles for article (PubMed ID: 29523800)
1. Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.
Byrne LM; Rodrigues FB; Johnson EB; De Vita E; Blennow K; Scahill R; Zetterberg H; Heslegrave A; Wild EJ
Sci Rep; 2018 Mar; 8(1):4260. PubMed ID: 29523800
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.
Rodrigues FB; Byrne L; McColgan P; Robertson N; Tabrizi SJ; Leavitt BR; Zetterberg H; Wild EJ
J Neurochem; 2016 Oct; 139(1):22-5. PubMed ID: 27344050
[TBL] [Abstract][Full Text] [Related]
3. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease.
Ou ZA; Byrne LM; Rodrigues FB; Tortelli R; Johnson EB; Foiani MS; Arridge M; De Vita E; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
Sci Rep; 2021 Feb; 11(1):3481. PubMed ID: 33568689
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.
Lowe AJ; Sjödin S; Rodrigues FB; Byrne LM; Blennow K; Tortelli R; Zetterberg H; Wild EJ
PLoS One; 2020; 15(8):e0233820. PubMed ID: 32804976
[TBL] [Abstract][Full Text] [Related]
5. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
Wild EJ; Boggio R; Langbehn D; Robertson N; Haider S; Miller JR; Zetterberg H; Leavitt BR; Kuhn R; Tabrizi SJ; Macdonald D; Weiss A
J Clin Invest; 2015 May; 125(5):1979-86. PubMed ID: 25844897
[TBL] [Abstract][Full Text] [Related]
6. Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington's disease.
van de Zande NA; Bulk M; Najac C; van der Weerd L; de Bresser J; Lewerenz J; Ronen I; de Bot ST
Neuroimage Clin; 2023; 39():103450. PubMed ID: 37327706
[TBL] [Abstract][Full Text] [Related]
7. Association Between Toll-Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease.
Vuono R; Kouli A; Legault EM; Chagnon L; Allinson KS; La Spada A; ; Biunno I; Barker RA; Drouin-Ouellet J
Mov Disord; 2020 Mar; 35(3):401-408. PubMed ID: 31724242
[TBL] [Abstract][Full Text] [Related]
8. Is there a role of Tau in Huntington's disease?
Zerr I; Bähr M
J Neurochem; 2016 Oct; 139(1):9-10. PubMed ID: 27651306
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium.
Halaas NB; Zetterberg H; Idland AV; Knapskog AB; Watne LO; Blennow K
J Alzheimers Dis; 2021; 81(2):667-677. PubMed ID: 33814433
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.
Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Nisticò R; Floris R; Garaci F; Hampel H;
J Alzheimers Dis; 2017; 59(4):1327-1334. PubMed ID: 28731449
[TBL] [Abstract][Full Text] [Related]
12. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.
Rodrigues FB; Byrne LM; Lowe AJ; Tortelli R; Heins M; Flik G; Johnson EB; De Vita E; Scahill RI; Giorgini F; Wild EJ
J Neurochem; 2021 Jul; 158(2):539-553. PubMed ID: 33797782
[TBL] [Abstract][Full Text] [Related]
13. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
[TBL] [Abstract][Full Text] [Related]
14. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
15. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
Wang L;
Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders.
Yilmaz A; Fuchs D; Price RW; Spudich S; Blennow K; Zetterberg H; Gisslén M
Curr HIV/AIDS Rep; 2019 Feb; 16(1):76-81. PubMed ID: 30649659
[TBL] [Abstract][Full Text] [Related]
17. Neurogranin as a Novel Biomarker in Alzheimer's Disease.
Agnello L; Gambino CM; Lo Sasso B; Bivona G; Milano S; Ciaccio AM; Piccoli T; La Bella V; Ciaccio M
Lab Med; 2021 Mar; 52(2):188-196. PubMed ID: 32926148
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.
Hall S; Janelidze S; Zetterberg H; Brix B; Mattsson N; Surova Y; Blennow K; Hansson O
Mov Disord; 2020 Mar; 35(3):513-518. PubMed ID: 31837067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
